<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830360</url>
  </required_header>
  <id_info>
    <org_study_id>SAPP004</org_study_id>
    <nct_id>NCT02830360</nct_id>
  </id_info>
  <brief_title>Antiarrhythmics or Ablation for Ventricular Tachycardia 2</brief_title>
  <acronym>VANISH2</acronym>
  <official_title>Ventricular Tachycardia Antiarrhythmics or AblatioN In Structural Heart Disease 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Sapp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiac Arrhythmia Network of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized clinical trial to assess whether catheter ablation or
      antiarrhythmic drug therapy provides the most effective control of important clinical
      outcomes for patients with prior myocardial infarction and sustained monomorphic ventricular
      tachycardia (VT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Implantable Defibrillators (ICDs) reduce sudden death and can terminate some VT without
      shocks, but they don't prevent VT; the most appropriate strategy to suppress VT remains
      unknown. Two randomized clinical trials have suggested that catheter ablation can
      significantly reduce the incidence of subsequent VT in patients after an initial episode.
      Neither trial, however, compared catheter ablation to active antiarrhythmic drug therapy.
      Randomized trials of antiarrhythmic drug therapy have demonstrated that therapy with either
      sotalol or amiodarone can reduce recurrent VT. Both antiarrhythmic drug and ablation therapy
      suffer from imperfect efficacy and the potential for significant side-effects. No study has
      compared ablation to drug therapy for first-line treatment. The VANISH study which compared
      ablation to aggressive antiarrhythmic drug therapy for patients who have failed initial drug
      therapy was published in May 2016, and demonstrated that for patients with drug-refractory
      VT, catheter ablation was superior to escalation of antiarrhythmic drug therapy. Benefits
      were seen in the group which had VT despite amiodarone. Event rates were similar between
      amiodarone and sotalol for patients with VT occurring despite sotalol, who were randomized to
      either new initiation of amiodarone or catheter ablation. These results do not address the
      clinical question of the most appropriate first line therapy for suppression of VT in persons
      with prior myocardial infarction, an ICD and VT.

      The trial hypothesis is: catheter ablation will, in comparison to antiarrhythmic drug therapy
      reduce the composite outcome of death at any time, appropriate ICD shock after 14 days,
      ventricular tachycardia storm after 14 days or treated sustained ventricular tachycardia
      below the detection rate of the ICD for patients with prior myocardial infarction and
      sustained monomorphic ventricular tachycardia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Time to any death occurring at any time post randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Appropriate ICD shock at least 14 days post randomization</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Time to first appropriate ICD shock after 14 days post randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VT storm at least 14 days post randomization</measure>
    <time_frame>6 years</time_frame>
    <description>Time to 3 or more episodes of VT within 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained VT requiring treatment at least 14 days post randomziation</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Time to any sustained VT greater below the detection rate of the ICD requiring cardioversion (electrical or chemical) or manual ICD therapy at least 14 days post randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appropriate ICD ATP at any time or after 14 days</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>any appropriate therapy delivered from the ICD at least 14 days post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate shocks</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>appropriate ICD shocks at any time post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VT storm at any time or after 14 days</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>3 or more episodes of VT occurring within 24 hours at any time post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained VT not treated by ICD at any time or after 14 days</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>any sustained VT greater than 30 seconds captured on a rhythm strip, monitor zone, holter monitor, or 12 lead ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained VT treated with appropriate any type of manual cardioversion after 14 days</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Any sustained VT greater than 30 seconds requiring manual cardioversion (ICD, external or pharmacologic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inappropriate ICD shocks at any time or after 14 days</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>all inappropriate shocks from the ICD at any time post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any ICD shock at any time or after 14 days</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Both appropriate and inappropriate shocks from the ICD at any time post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any ventricular arrhythmia event at any time or after 14 days (composite of appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion)</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>All ventricular arrhythmias including a composite of: appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion), VT storm/incessant VT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICD shocks (all cause)</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>the number of all shocks from any cause will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Anti-tachycardia pacing (ATP)</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>The total of all ATP delivered from the ICD will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICD appropriate therapy</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Total number of therapies which received appropriate ICD therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of VT storm events</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Total number of VT storms (3 episodes of VT within 24 hours)/ incessant VT will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sustained VT events</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Total number of sustained VT (greater than 30 seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventricular arrhythmia events</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>This is a composite of appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion, or VT storm/incessant VT. VT events which do not terminate despite exhausting ICD therapies will be considered incessant VT and included within the definition of VT storm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission for cardiac causes</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Hospitalizations greater than 24 hours due to a cardiovascular cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ablation procedural complications or antiarrhythmic drug adverse effects (this may require a separate substudy, depending on data complexity)</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Periprocedural complications and adverse drug reactions will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to any serious adverse events</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Serious events is any event which causes death, hospitalization, is life threatening and is directly related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects from anti-arrhythmic medication</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Any dose change or discontinuation of anti-arrhythmic medication due to abnormal blood tests (including kidney function, liver function, thyroid function) or any perceived side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - SF36</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Will include responses from the Short Form 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - EQ5D</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Will include responses from the Euroquol 5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - HADS</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Will include responses from the Hospital Anxiety and Depression Scale quesionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Quality adjusted life years (QALYs) will be derived from the case report forms and the questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Escalation and De-escalation of antiarrhythmic medication</measure>
    <time_frame>6 years (including pilot study data)</time_frame>
    <description>Any increase or decrease in the dosage of antiarrhythmic medication either due to inefficacy or side effects will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Ventricular Tachycardia (VT)</condition>
  <arm_group>
    <arm_group_label>VT catheter ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter ablation of ventricular tachycardia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiarrhythmic Drug Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be prescribed either oral amiodarone or sotalol daily (dosage and frequency to be determined based on patient's clinical presentation at the time of the qualifying arrhythmia).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrythmic Drug Therapy</intervention_name>
    <description>Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)</description>
    <arm_group_label>Antiarrhythmic Drug Therapy</arm_group_label>
    <other_name>Amiodarone (Cordarone) or Sotalol (Sotacor)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation</intervention_name>
    <description>Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.</description>
    <arm_group_label>VT catheter ablation</arm_group_label>
    <other_name>VT ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior Myocardial Infarction and

          -  One of the following VT events while not being treated with amiodarone, sotalol, or
             another class I or class III antiarrhythmic drug) within the last 6 months:

               -  Sustained monomorphic VT documented on 12-lead ECG or rhythm strip terminated by
                  pharmacologic means or DC cardioversion

               -  ≥3 episodes of VT treated with antitachycardia pacing (ATP), at least one of
                  which was symptomatic

               -  ≥ 5 episodes of VT treated with antitachycardia pacing (ATP) regardless of
                  symptoms

               -  ≥1 appropriate ICD shocks,

               -  ≥3 VT episodes within 24 hours

        Exclusion Criteria:

          -  Unable or unwilling to provide informed consent.

          -  Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST
             segment changes demonstrated on ECG) or another reversible cause of VT (e.g.
             drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary
             revascularization (&lt;90 days bypass surgery, &lt;30 days percutaneous coronary
             intervention), or have CCS functional class IV angina. Note that biomarker level
             elevation alone after ventricular arrhythmias does not denote acute coronary syndrome
             or active ischemia.

          -  Are ineligible to take the antiarrhythmic drug to which they would be assigned due to
             allergy, intolerance or contraindication

          -  Are known to have protruding left ventricular thrombus or mechanical aortic and mitral
             valves

          -  Have had a prior catheter ablation procedure for VT

          -  Are in renal failure (Creatinine clearance &lt;15 mL/min), have NYHA Functional class IV
             heart failure, or a systemic illness likely to limit survival to &lt;1 year

          -  Have had recent ST elevation myocardial infarction or non-ST elevation MI (&lt; 30 days);
             note that biomarker elevation alone after ventricular arrhythmias does not denote MI.

          -  Are pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John L Sapp, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ratika Parkash, MD MSc FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>Nova Scotia Health Authoriry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony L Tang, MD FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George A Wells, BSc MSc PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William G Stevenson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff Healey, MD FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>Population Health Research Institute, McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen A Giddens, RDMS RDCS</last_name>
    <phone>9024732758</phone>
    <email>karen.giddens@nshealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John L Sapp, MD FRCPC</last_name>
    <phone>902 473 4272</phone>
    <email>john.sapp@nshealth.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizabeth Roper, MHS</last_name>
    </contact>
    <investigator>
      <last_name>Edmond Cronin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libby Salberg</last_name>
      <phone>615-322-2281</phone>
      <email>libby.salberg@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Arvindh Kanagasundram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2W 1S7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Tonelli, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Vikas Kuriachan, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Welch</last_name>
      <phone>780-407-8007</phone>
      <email>Ron.Welch@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Tomasz Hrusczkowski, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fraser Health Authority - Royal Columbian Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V3T OH1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Chunick</last_name>
      <phone>604-587-4681</phone>
      <email>susan.chunick@fraserhealth.ca</email>
    </contact>
    <investigator>
      <last_name>Stan Tung, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S.F. Paul Man, MD, FRCPC</last_name>
      <phone>(604) 806-8495</phone>
      <email>pman@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Marc Deyell, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Jubilee Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 1J8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Trytten</last_name>
      <phone>250-370-8485</phone>
      <email>Cindy.Trytten@viha.ca</email>
    </contact>
    <investigator>
      <last_name>Chris Lane, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Giddens</last_name>
      <phone>902 473 2758</phone>
      <email>karen.giddens@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>John L Sapp, MD FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 8E7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ted Scott, PhD</last_name>
      <phone>905.521.2100 ext. 72290</phone>
      <email>scottted@HHSC.CA</email>
    </contact>
    <investigator>
      <last_name>Guy Amit, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's University Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Deeley, PhD</last_name>
      <phone>613-549-6666 x.3344</phone>
      <email>Roger.Deeley@Kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Damian Redfearn, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Terlevic</last_name>
    </contact>
    <investigator>
      <last_name>Umjeet Jolly, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Litchfield</last_name>
      <email>cheryl.litchfield@lawsonresearch.com</email>
    </contact>
    <investigator>
      <last_name>Lorne Gula, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Fraser, CA, MBA</last_name>
    </contact>
    <investigator>
      <last_name>Pablo nery, ZMD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Slutsky, MD</last_name>
      <phone>416 864-5637</phone>
      <email>SlutskyA@smh.ca</email>
    </contact>
    <investigator>
      <last_name>Paul Angaran, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Lefebvre</last_name>
    </contact>
    <investigator>
      <last_name>Lena Rivard, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Costas N Karatzas, MSc, PhD</last_name>
      <phone>514-934-1934 ext. 71532</phone>
      <email>costas.karatzas@mail.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Vidal Essebag, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universitaire de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Poitout, DVM, PhD, FCAHS</last_name>
      <phone>514 890-8044</phone>
      <email>vincent.poitout@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc Raymond, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de cardiologie et pneumologie de Quebec - Laval University Hosptial</name>
      <address>
        <city>Quebec CIty</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Clavet</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Francois Sarazzin, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Univesitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Bernier, MAP, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Francois Roux, Md, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Acquitaine</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Phillippe Vigouroux</last_name>
    </contact>
    <investigator>
      <last_name>Fred Sacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU - University Hospital Nancy</name>
      <address>
        <city>Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Vigouroux</last_name>
    </contact>
    <investigator>
      <last_name>Christian De Chillou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>John Sapp</investigator_full_name>
    <investigator_title>Staff Physician, Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Antiarrhythmic drug therapy</keyword>
  <keyword>VT Catheter ablation</keyword>
  <keyword>ICD Therapy</keyword>
  <keyword>Ischemic Heart Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Sotalol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

